Elanco Animal Health Incorporated (ELAN)
| Market Cap | 11.21B +4.2% |
| Revenue (ttm) | 5.02B +12.0% |
| Net Income | -199.00M |
| EPS | -0.41 |
| Shares Out | 499.62M |
| PE Ratio | n/a |
| Forward PE | 18.85 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 263,112 |
| Open | 22.62 |
| Previous Close | 22.52 |
| Day's Range | 22.18 - 22.67 |
| 52-Week Range | 19.40 - 27.98 |
| Beta | 1.71 |
| Analysts | Buy |
| Price Target | 30.31 (+35.13%) |
| Earnings Date | Nov 6, 2026 |
About ELAN
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal fam... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for ELAN stock is "Buy." The 12-month stock price target is $30.31, which is an increase of 35.13% from the latest price.
News
Elanco CPO Dave Kinard to retire, Jamie Preston to succeed
Elanco (ELAN) announced the appointment of Jamie Preston as executive VP and chief people officer, or CPO, effective November 3. Preston succeeds Dave Kinard, who intends to retire at the…
Elanco Animal Health Appoints Jamie Preston as Chief People Officer
Preston brings more than two decades of global HR leadership and workforce innovation experience; Dave Kinard to retire at year-end INDIANAPOLIS, Oct. 22, 2026 /PRNewswire/ -- Elanco Animal Health Inc...
Elanco downgraded to Hold from Buy at Jefferies
Jefferies downgraded Elanco (ELAN) to Hold from Buy with a price target of $24, down from $31. The firm cites the company’s softer pricing environment for the downgrade. The firm…
Elanco initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of Elanco (ELAN) with a Buy rating and $32 price target The company has a diversified pharmaceuticals portfolio serving both pets and farm animals, the analyst…
What Growing Up on a Farm Taught Elanco's CEO
One of Jeff Simmons' pivotal leadership lessons came when he was 7 years old. Now CEO of Elanco Animal Health, Simmons said his family's upstate New York grape farm had been devastated by a hailstorm....
Elanco Animal Health Transcript: Bank of America Global Healthcare Conference
The event highlighted robust growth, innovation, and cash generation, with a strong pipeline of differentiated products and a focus on margin expansion. Strategic international rollout, operational efficiency, and targeted investments in vaccines and environmental solutions position the business for sustained mid- to high-single-digit growth and expanding profitability.
Elanco to Participate in BofA Securities Global Healthcare Conference 2026
INDIANAPOLIS, Sept. 17, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the BofA Securities Global Healthcare Conference 2026 on September 22, 2026.
Elanco Animal Health Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Pet health and farm animal markets are experiencing robust growth, driven by innovation, omni-channel expansion, and resilient demand. Differentiated products like Zenrelia, Quattro, and Befrena are gaining share, while margin improvements and a strong pipeline support long-term growth through 2027 and beyond.
Expanding Tick and Itch Season Supports Momentum in Elanco Innovation, Meeting Pet Owner Demand for Health and Wellness Care
Innovation that protects against these pests is driving stronger Elanco base business and overall share gains. Elanco confirms U.S. Pet Health is on track to expectations of high-single digit to low d...
Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement
INDIANAPOLIS, Sept. 11, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2026 financial results on Friday, November 6, 2026.
Elanco to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
INDIANAPOLIS, Sept. 10, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026.
Elanco announces completion of manufacturing expansion at Elwood
Elanco (ELAN) Animal Health announced the on-time completion of a 25,000-square-foot manufacturing expansion of its Elwood, Kansas manufacturing site. As one of only two animal health companies with m...
Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility
The completed 25,000-square-foot Elwood site expansion bolsters Elanco's monoclonal antibody (mAb) production; supports delivery of next-generation pipeline INDIANAPOLIS, Aug. 26, 2026 /PRNewswire/ --...
Elanco CLiK Extra receives FDA Emergency Use Authorization
Elanco (ELAN) announced it has received Emergency Use Authorization from the U.S. Food and Drug Administration for CLiK Extra wound spray for application on or around wounds to prevent infestations…
Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species
Vigilance and early intervention are key to minimizing animal injury and limiting the parasite's spread, according to Elanco's technical experts Emergency Use Authorization for Elanco's CLiK Extra pro...
Elanco CEO on Boosted Forecast, Surge in Tick Bites
Elanco Animal Health President and CEO Jeff Simmons discusses what's behind the company's increased profit and revenue forecasts. Speaking on "Bloomberg The Close," Simmons also comments on the recent...
Elanco price target raised to $33 from $31 at UBS
UBS analyst Andrea Alfonso raised the firm’s price target on Elanco (ELAN) to $33 from $31 and keeps a Buy rating on the shares.
Elanco price target raised to $34 from $31 at Citi
Citi raised the firm’s price target on Elanco (ELAN) to $34 from $31 and keeps a Buy rating on the shares.
Elanco price target raised to $30 from $29 at KeyBanc
KeyBanc raised the firm’s price target on Elanco (ELAN) to $30 from $29 and keeps an Overweight rating on the shares. The firm notes the company posted a solid beat…
Elanco Animal Health Earnings Call Transcript: Q2 2026
Q2 2026 saw 8% organic revenue growth, margin expansion, and strong innovation-driven gains, especially from Zenrelia and Credelio Quattro. Full-year guidance was raised for revenue, EBITDA, and EPS, with continued investment in launches and productivity initiatives.
Elanco Animal Health Earnings release: Q2 2026
Elanco Animal Health released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Elanco Animal Health Slides: Q2 2026
Elanco Animal Health has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Elanco Animal Health Quarterly report: Q2 2026
Elanco Animal Health has published its Q2 2026 quarterly earnings report on August 5, 2026.
Elanco reports Q2 adjusted EPS 34c, consensus 27c
Reports Q2 revenue $1.37B, consensus $1.31B. “Elanco’s (ELAN) second quarter results demonstrate our momentum and leadership in the attractive animal health industry,” stated Jeff Simmons, President a...
Elanco Animal Health Reports Second Quarter 2026 Results
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2026 Financial Results: Revenue of $1,368 million, an increase of 10% year-over-year; 8% or...